BSX Is Down 34% YTD and the Watchman Just Missed — Is This Stock Already Dead on Arrival?

Let's talk about $BSX, because ouch. Boston Scientific just fell to its lowest level since 2024 — down roughly 9% on the session and 34% year-to-date — after its Watchman heart implant trial results came in as, and we're quoting analysts here, 'not the home run scenario.' Sir, this isn't even a bunt. With sustained selling pressure well beyond a single bad trial, the street is treating this like a structural problem, not a one-day stumble.

Meanwhile, $PANW is having a soap opera moment. The stock is still down 16% year-to-date and 30% from October highs, but CEO Nikesh Arora dropped $10 million of his own cash buying shares — the biggest single-day gain since April followed. Cramer agrees: he argued on Mad Money that AI agents like Anthropic's rumored new model actually increase demand for cybersecurity, not kill it. Retail traders are watching that insider buy like it's a buy signal from God. And then there's $SYY, which posted its worst single-day drop in recent memory — down 15% — reminding everyone that even the boring food distribution trade isn't safe when oil tops $104/barrel and input costs are spiraling.

Earnings season is essentially being held hostage by a geopolitical crisis, a potential Fed policy pivot, and an AI model that hasn't even launched yet — which is honestly very on-brand for 2026.